Form: 424B3

Prospectus [Rule 424(b)(3)]

November 17, 2026

Prospectus Supplement

Filed Pursuant to Rule 424(b)(3)

(to Prospectus dated April 24, 2026)

Registration No. 333-295140

img246905196_0.jpg

This prospectus supplement updates, amends and supplements the prospectus dated April 24, 2026 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-295140). Capitalized terms used in this prospectus supplement and not otherwise defined herein have the meanings specified in the Prospectus.

This prospectus supplement is being filed to update, amend and supplement the information included in the Prospectus with the information contained in our Current Report on Form 8-K filed with the Securities and Exchange Commission on November 17, 2026, which is set forth below.

This prospectus supplement is not complete without the Prospectus. This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference.

Our common stock is traded on the New York Stock Exchange under the symbol “EVMN.” On November 17, 2026, the last reported sale price of our common stock was $7.04 per share.

Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described in the section titled “Risk Factors” beginning on page 5 of the prospectus, and under similar headings in any amendments or supplements to the Prospectus.

Neither the Securities and Exchange Commission nor any state securities commission or other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus supplement or the Prospectus. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is November 17, 2026.

 


 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 13, 2026

Evommune, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

001-42938

85-0742575

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

1891 Page Mill Road

Palo Alto, CA

94304

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (925) 247-4487

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

EVMN

The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Retention Awards

On November 13, 2026, the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Evommune, Inc. (the “Company”) approved the entry of an amendment to the applicable employment agreement(s) (each an “Amendment”) with certain executive officers of the Company, including the Chief Executive Officer, the Chief Financial Officer, and the Chief Business & Legal Officer, pursuant to which, effective upon the execution of the Amendment by each officer (each, an “Amendment Effective Date”), such officer will be eligible to earn a cash retention award (each a “Retention Award”).

The amounts of such Retention Awards for the Chief Executive Officer, the Chief Financial Officer, and the Chief Business & Legal Officer are set forth below:

 

Luis Peña, President and Chief Executive Officer

$686,600

Kyle Carver, Chief Financial Officer

$565,000

Gregory Moss, Chief Business & Legal Officer

$595,000

 

The Retention Awards, less any necessary deductions, will be payable by the Company in two equal installments subject to vesting. The first installment will vest on the first anniversary of the applicable Amendment Effective Date, subject to a continuous employment condition, which can be met if such officer remains employed at the Company on such vesting date, without having received a notice of the Company’s intention to terminate such officer for Cause or having submitted notice of resignation without Good Reason, as those terms are defined in the applicable employment agreement (the “Continuous Employment Condition”). The second installment will vest on the second anniversary of the applicable Amendment Effective Date, subject to satisfaction of both the Continuous Employment Condition as of such date and a stock price condition, which can be met if either: (i) after the first anniversary and on or before the second anniversary of the applicable Amendment Effective Date, the average closing price of the Company’s common stock during any 15 consecutive trading days is at or above $15.00 per share; or (ii) the closing price of the Company’s common stock is at or above $15.00 per share on the second anniversary (or, if not a trading day, the immediately preceding trading day) (the “Stock Price Condition”), each subject to any stock split, reverse stock split, stock dividend, recapitalization or similar adjustment.

If a Change in Control (as defined in the Amendment) occurs on or before the second anniversary of the applicable Amendment Effective Date and the officer remains employed by the Company through the closing of such Change in Control, any portion of the Retention Award that has not previously been earned will become fully earned as of such closing. In the event an officer’s employment is terminated by the Company without Cause (as defined in each Amendment) or by such officer for Good Reason (as defined in each Amendment) (a “Qualifying Termination”), if such Qualifying Termination occurs on or before the first anniversary of the applicable Amendment Effective Date, such officer will be eligible to receive the first installment, and if such Qualifying Termination occurs after the first anniversary and on or before the second anniversary of the applicable Amendment Effective Date, such officer will be eligible to receive the second installment upon the satisfaction of the Stock Price Condition, and in each case, subject to the execution of a release agreement by such officer.

The foregoing description of the Retention Awards and the terms of the Amendments do not purport to be complete and is qualified in its entirety by reference to the form of the Amendments, a copy of which will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the fiscal year ending December 31, 2026.

Repricing of Certain Outstanding Stock Options

On November 13, 2026, the Committee approved an option repricing pursuant to which each Eligible Option (as defined below) was immediately repriced such that the exercise price per share for such Eligible Option was reduced to $7.63, the closing price of the Company’s common stock as of the November 13, 2026 (the “Repricing Effective Date”), subject to certain retention requirements outlined below. The repricing generally applies to options to purchase shares of the Company’s common stock that: (i) were granted under the Company’s 2025 Equity Incentive Plan (the “Plan”); (ii) as of the Repricing Effective Date, are held by the Company’s then-current employees and non-employee directors (each, an “Eligible Participant”); and (iii) have an exercise price per share equal to or greater than $16.00 (the “Eligible Options”). The Eligible Options include underwater options held by each of Luis C. Peña, the Company’s President and Chief Executive Officer (options to purchase 1,088,261 shares with original exercise prices ranging from $16.00 to $26.77), Kyle Carver, the Company’s Chief Financial Officer (options to purchase 378,354 shares with original exercise prices ranging from $16.00 to $26.77) and Gregory Moss, the Company’s Chief Business & Legal Officer (options to purchase 408,775 shares with original exercise prices ranging from $16.00 to $26.77).

1


 

In order to exercise the Eligible Options at the reduced exercise price, Eligible Participants are required to remain in Continuous Service (as defined under the Plan) with the Company through the end of the relevant Retention Period (as hereinafter defined). The “Retention Period” begins on the Repricing Effective Date and ends on the earliest of the following: (i) the date 12 months following the Repricing Effective Date; (ii) a Change in Control (as defined in the Plan); and (iii) the Eligible Participant’s termination of Continuous Service (a) due to such individual’s death or Disability (as defined in the Plan), (b) by the Company (or successor entity in a Change in Control) other than for Cause (as defined in the Plan) or (c) due to such individual’s resignation on or following a Change in Control under certain circumstances constituting “Good Reason.” “Good Reason” is defined as set forth in such individual’s employment agreement or other written agreement with the Company, after complying with a specified notice and cure period.

If an Eligible Participant exercises an Eligible Option in advance of the end of the relevant Retention Period (as defined below), such Eligible Participant will be required to pay a premium exercise price equal to the original exercise price per share of such Eligible Option. No other changes were made to the Eligible Options as a result of the repricing, including with respect to the vesting schedules or expiration dates of or the number of shares underlying the Eligible Options.

The Committee approved the repricing after careful consideration and discussion of various alternatives and a review of other applicable factors with the advice of the Company’s independent compensation consultant. The Committee designed the repricing, with the premium exercise price applicable during the Retention Period, to provide added incentive to retain and motivate the Eligible Participants to continue to work in the best interests of the Company and its stockholders without incurring the stock dilution resulting from significant additional equity grants or significant additional cash expenditures resulting from additional cash compensation. As of the date of approval of the repricing, nearly all of the stock options held by Company employees were “underwater,” with exercise prices well above the current market price of the Company’s common stock. The total number of shares underlying all Eligible Options is 3,692,840 shares. The Eligible Options have current exercise prices ranging from $16.00 to $26.77 per share.

 

2


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Evommune, Inc.

Date: November 17, 2026

By:

/s/ Luis Peña

Luis Peña

President and Chief Executive Officer

 

3